ORFADIN Drug Patent Profile

Which patents cover Orfadin, and what generic alternatives are available?

Orfadin is a drug marketed by Swedish Orphan and is included in two NDAs. There is one patent protecting this drug.

This drug has twenty-four patent family members in twenty-two countries.

The generic ingredient in ORFADIN is nitisinone. There are two drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the nitisinone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Orfadin

A generic version of ORFADIN was approved as nitisinone by NOVITIUM PHARMA on August 26^th, 2019.

Summary for ORFADIN

International Patents:	24
US Patents:	1
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	95
Clinical Trials:	12
Patent Applications:	809
Drug Prices:	Drug price information for ORFADIN
What excipients (inactive ingredients) are in ORFADIN?	ORFADIN excipients list
DailyMed Link:	ORFADIN at DailyMed

See drug prices for ORFADIN

Recent Clinical Trials for ORFADIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sutphin Drugs	N/A
Parexel	Phase 1
Cycle Pharmaceuticals Ltd.	Phase 1

See all ORFADIN clinical trials

Pharmacology for ORFADIN

Drug Class	4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor
Mechanism of Action	Cytochrome P450 2C9 Inhibitors Cytochrome P450 2E1 Inducers Hydroxyphenylpyruvate Dioxygenase Inhibitors Organic Anion Transporter 1 Inhibitors Organic Anion Transporter 3 Inhibitors

US Patents and Regulatory Information for ORFADIN

ORFADIN is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Swedish Orphan	ORFADIN	nitisinone	CAPSULE;ORAL	021232-001	Jan 18, 2002	AB	RX	Yes	No
Swedish Orphan	ORFADIN	nitisinone	CAPSULE;ORAL	021232-004	Jun 13, 2016	AB	RX	Yes	Yes
Swedish Orphan	ORFADIN	nitisinone	CAPSULE;ORAL	021232-002	Jan 18, 2002	AB	RX	Yes	No
Swedish Orphan	ORFADIN	nitisinone	CAPSULE;ORAL	021232-003	Jan 18, 2002	AB	RX	Yes	No
Swedish Orphan	ORFADIN	nitisinone	SUSPENSION;ORAL	206356-001	Apr 22, 2016		RX	Yes	Yes	9,301,932		Y

Expired US Patents for ORFADIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Swedish Orphan	ORFADIN	nitisinone	CAPSULE;ORAL	021232-001	Jan 18, 2002	5,006,158
Swedish Orphan	ORFADIN	nitisinone	CAPSULE;ORAL	021232-003	Jan 18, 2002	5,550,165
Swedish Orphan	ORFADIN	nitisinone	CAPSULE;ORAL	021232-001	Jan 18, 2002	5,550,165
Swedish Orphan	ORFADIN	nitisinone	CAPSULE;ORAL	021232-003	Jan 18, 2002	5,006,158
Swedish Orphan	ORFADIN	nitisinone	CAPSULE;ORAL	021232-002	Jan 18, 2002	5,550,165

EU/EMA Drug Approvals for ORFADIN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
MendeliKABS Europe Ltd	Nitisinone MDK (previously Nitisinone MendeliKABS)	nitisinone	EMEA/H/C/004281Treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT 1) in combination with dietary restriction of tyrosine and phenylalanine.	Withdrawn	yes	no	no	2017-08-24
Cycle Pharmaceuticals (Europe) Ltd	Nityr	nitisinone	EMEA/H/C/004582Treatment of adult and paediatric patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.	Authorised	yes	no	no	2018-07-26
Swedish Orphan Biovitrum International AB	Orfadin	nitisinone	EMEA/H/C/000555Hereditary tyrosinemia type 1 (HT 1)Orfadin is indicated for the treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT 1) in combination with dietary restriction of tyrosine and phenylalanine.Alkaptonuria (AKU)Orfadin is indicated for the treatment of adult patients with alkaptonuria (AKU).	Authorised	no	no	no	2005-02-21

International Patents for ORFADIN

When does loss-of-exclusivity occur for ORFADIN?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Croatia

Cyprus

Denmark

European Patent Office

Hungary

Israel

Japan

Mexico

New Zealand

Poland

Russian Federation

San Marino

Serbia

Slovenia

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ORFADIN around the world.

Country	Patent Number	Title	Estimated Expiration
Slovenia	2723320
Japan	6038132
China	85109772
Japan	S58180451	2-(2-SUBSTITUTED BENZOYL)-1,3-CYCLOHEXANDIONES
Greece	3029841

Supplementary Protection Certificates for ORFADIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0186118	SPC/GB05/029	United Kingdom		PRODUCT NAME: MESOTRIONE (2-(4-METHYLSULPHONYL-2-NITROBENZOYL)-1,3CYCLOHEXANEDIONE); REGISTERED: AU 2726 20001016; UK 0309 OF 2005 20050218
0591275	CA 2005 00029	Denmark
0186118	C350003	Netherlands		PRODUCT NAME: MESOTRIONE, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: 12204N 20010504
0186118	SPC/GB05/037	United Kingdom		PRODUCT NAME: A COMBINATION OF TERBUTHYLAZINE AND MESOTRIONE; REGISTERED: DK 1-186 20050203; UK 0805 OF 2005 20050425
0591275	05C0024	France		PRODUCT NAME: NITISINONE; REGISTRATION NO/DATE: EU/1/04/303/001 20050221

ORFADIN Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

ORFADIN (nifurtimox) is a drug indicated for the treatment of Chagas disease (American trypanosomiasis). The market for ORFADIN is characterized by its niche indication, reliance on specific patient populations, and the impact of global health initiatives and drug accessibility programs. The financial trajectory of ORFADIN is primarily shaped by prescription volumes, reimbursement policies, and the cost of goods.

What is the Current Market Size and Projected Growth for ORFADIN?

The global market for ORFADIN is relatively small due to the endemic nature of Chagas disease, which primarily affects Latin America. Precise market size figures are not widely published in public financial reports due to the drug's status as a neglected tropical disease (NTD). However, estimates suggest that the annual sales for ORFADIN are in the low tens of millions of U.S. dollars globally.

Projected growth is expected to be moderate, driven by increased diagnosis and treatment rates in endemic regions, and potential expansion into non-endemic areas with significant immigrant populations from Chagas-endemic countries.

Key Market Drivers:

• Increased Awareness and Diagnosis: Efforts by global health organizations to improve diagnosis of Chagas disease in both endemic and non-endemic regions are expected to lead to higher prescription volumes.
• Government and NGO Support: Public health programs and non-governmental organizations (NGOs) often subsidize or procure NTD treatments, including ORFADIN, thereby influencing its accessibility and uptake.
• Pediatric Patient Population: ORFADIN is a crucial treatment for children infected with Trypanosoma cruzi, representing a significant portion of the patient demographic requiring treatment.
• Limited Therapeutic Alternatives: For certain stages of Chagas disease, ORFADIN remains one of the primary treatment options, supporting sustained demand.

Market Challenges:

• Geographic Concentration: The majority of Chagas disease cases are found in specific Latin American countries, limiting the broad market appeal of ORFADIN.
• Pricing and Affordability: While efforts are made to ensure accessibility, the cost of treatment can still be a barrier in resource-limited settings.
• Regulatory Hurdles: Navigating diverse regulatory landscapes in different countries can impact market penetration.
• Supply Chain Complexities: Ensuring consistent and reliable supply of ORFADIN to remote and underserved areas presents logistical challenges.

Who are the Primary Stakeholders in the ORFADIN Market?

The stakeholders involved in the ORFADIN market include pharmaceutical manufacturers, distributors, healthcare providers, regulatory bodies, patient advocacy groups, and governmental health organizations.

Pharmaceutical Manufacturer:

Bayer AG is the primary manufacturer and distributor of ORFADIN. The company has been instrumental in ensuring the availability of the drug globally, particularly through access programs.

Distributors and Supply Chain Partners:

Various local and international distributors play a role in getting ORFADIN to clinics and pharmacies in endemic regions. These partnerships are critical for overcoming logistical challenges.

Healthcare Providers:

Physicians, infectious disease specialists, and public health clinics in both endemic and non-endemic countries are the direct prescribers of ORFADIN. Their diagnostic capabilities and treatment protocols directly influence demand.

Regulatory Authorities:

Agencies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national health ministries in Latin American countries approve and regulate the marketing and distribution of ORFADIN.

Governmental and Global Health Organizations:

Organizations such as the World Health Organization (WHO), the Pan American Health Organization (PAHO), and national ministries of health are key players in advocating for Chagas disease control, supporting diagnosis, and facilitating access to treatments like ORFADIN. They often fund treatment programs and procure large quantities of the drug.

Patient Advocacy Groups:

These groups raise awareness about Chagas disease, advocate for improved access to diagnosis and treatment, and provide support to patients and their families. Their influence can drive policy changes and increase demand for effective therapies.

What is the Patent Landscape and Exclusivity for ORFADIN?

ORFADIN (nifurtimox) was initially developed decades ago. The original patents related to its discovery and composition of matter have long expired. However, as a medication for a neglected tropical disease, its manufacturing and distribution have been managed under specific arrangements to ensure continued availability.

Key Considerations:

• Expired Composition of Matter Patents: The fundamental patents covering nifurtimox itself have expired, meaning the active pharmaceutical ingredient is no longer protected by these original patents.
• Manufacturing Process Patents: While less common to be extensively publicized for older drugs, there may be patents related to specific improved manufacturing processes or formulations that could offer some limited protection.
• Orphan Drug Exclusivity: In regions like the United States, nifurtimox has been designated as an orphan drug for Chagas disease. This designation grants market exclusivity for a period (typically seven years in the U.S. from approval for that indication) even if the underlying patents have expired. This exclusivity prevents the FDA from approving a similar drug for the same orphan indication during that period, unless specific exceptions apply. [1]
• Regulatory Data Protection: Similar to orphan drug exclusivity, regulatory data protection provides a period during which generic manufacturers cannot rely on the innovator's clinical trial data to gain marketing approval.
• Bayer's Role: Bayer AG, as the current supplier, likely holds intellectual property related to its specific manufacturing methods and quality control processes, ensuring the integrity and consistent supply of the branded product.

The absence of strong, long-term patent protection for the active ingredient means that the primary barrier to generic competition for ORFADIN is not patent expiry but rather the specialized nature of its market, manufacturing complexity, and the continued efforts of the incumbent manufacturer to ensure supply and manage access.

What are the Financial Performance Indicators and Revenue Streams for ORFADIN?

The financial performance of ORFADIN is not typically broken out as a distinct revenue line item in the public financial reports of its manufacturer, Bayer AG, due to its niche status and integration within broader portfolio reporting. However, its revenue is primarily generated through direct sales to healthcare systems, national health programs, and in some cases, direct-to-consumer markets where applicable and regulated.

Revenue Streams:

• Direct Sales to Governments and NGOs: A significant portion of ORFADIN sales is likely to national health ministries and international health organizations that procure the drug for their public health programs in endemic countries. These sales often involve volume-based contracts and negotiated pricing.
• Sales to Hospitals and Clinics: In countries where Chagas disease is treated in healthcare facilities, sales are made to hospitals and specialized clinics.
• Pharmacy Sales: In countries with a private healthcare system and regulatory approval, ORFADIN may be sold through pharmacies.

Financial Performance Indicators (Estimates and Influencing Factors):

• Sales Volume: The number of treatment courses prescribed and dispensed directly correlates with revenue. Increased diagnosis and treatment campaigns are key to boosting volume.
• Average Selling Price (ASP): While specific ASPs are not public, they are influenced by negotiated prices with bulk purchasers (governments, NGOs), reimbursement rates, and the cost of managing specialized supply chains. Given its status as an NTD treatment, pricing strategies often balance commercial viability with accessibility.
• Cost of Goods Sold (COGS): The manufacturing complexity, quality control requirements, and specialized raw materials contribute to the COGS. As a niche product, economies of scale might be limited compared to blockbuster drugs.
• Research and Development (R&D) Spend: R&D associated with ORFADIN is likely minimal, focused more on process optimization and post-market surveillance rather than new clinical trials, given its established profile.
• Marketing and Distribution Costs: These are significant due to the need for targeted outreach in endemic regions, complex logistics, and engagement with public health stakeholders.

Given the estimated low tens of millions in global annual sales, ORFADIN is a non-core product within Bayer's broader pharmaceutical division but holds strategic importance in its commitment to addressing neglected diseases.

How is ORFADIN Priced and Reimbursed?

The pricing and reimbursement landscape for ORFADIN is complex and highly variable, reflecting its status as a treatment for a neglected tropical disease (NTD) with specific patient populations and a strong public health component.

Pricing Strategies:

• Tiered Pricing: Manufacturers often employ tiered pricing strategies, offering lower prices in low- and middle-income countries (LMICs) where the disease is endemic and affordability is a major concern. Higher prices may be charged in high-income countries or for specific market segments.
• Cost-Plus Considerations: While not exclusively a cost-plus model, the pricing must account for manufacturing costs, specialized distribution, and the investment in ensuring continuous supply for a disease that might not generate substantial commercial returns.
• Value-Based Pricing (Limited Applicability): Traditional value-based pricing models, which assess a drug's economic benefit to the healthcare system, have limited applicability for NTDs like Chagas disease, where the primary payers are often governments or global health initiatives focused on public health outcomes rather than direct economic return.
• Negotiated Contracts: A significant portion of ORFADIN is sold through negotiated contracts with national health programs, international organizations (e.g., PAHO), and NGOs. These contracts often involve volume discounts and tailored pricing agreements.

Reimbursement Landscape:

• Government and Public Health Funding: In endemic countries, ORFADIN is often procured and distributed by national health ministries or through public health programs funded by governmental budgets or international aid. This is the primary mechanism for reimbursement.
• Orphan Drug Status Impact: In countries with orphan drug legislation (e.g., U.S. FDA, EMA), the designation can influence reimbursement decisions by creating a perception of necessity for a rare disease treatment. However, the actual reimbursement amount is still subject to payer policies.
• Insurance Coverage (Limited): In high-income countries with significant immigrant populations from endemic regions, ORFADIN may be covered by private health insurance or national healthcare systems. Coverage decisions by insurers depend on evidence of efficacy, safety, cost-effectiveness, and clinical guidelines.
• Patient Assistance Programs (PAPs): Pharmaceutical companies, including Bayer, may operate patient assistance programs to help eligible patients in specific regions or circumstances access the drug at a reduced cost or for free, further influencing effective pricing and accessibility.
• Global Funds and Initiatives: Funding from global health initiatives and grants (e.g., from the Bill & Melinda Gates Foundation or other philanthropic organizations) can indirectly subsidize the cost of NTD treatments, impacting the effective price paid.

The overall pricing and reimbursement strategy for ORFADIN prioritizes ensuring access for the target patient population while balancing the need for manufacturing sustainability.

What are the Regulatory and Clinical Considerations for ORFADIN?

ORFADIN (nifurtimox) has a long history of use, but its clinical application and regulatory status are shaped by ongoing research, evolving treatment guidelines, and the specific challenges of managing Chagas disease.

Regulatory Status:

• FDA Approval: In the United States, nifurtimox was approved by the FDA in 2017 for the treatment of pediatric patients (12 years of age and younger) with Chagas disease. This approval was based on a New Drug Application (NDA) filed by Bayer and granted under its orphan drug designation. [1]
• EMA Approval: In Europe, nifurtimox has been available for a longer period, with marketing authorization granted by the European Medicines Agency (EMA) for the treatment of Chagas disease.
• National Approvals: ORFADIN is approved and available in many Latin American countries where Chagas disease is endemic, often through national regulatory processes.
• Orphan Drug Designation: The drug holds orphan drug status in major markets, providing market exclusivity and potentially influencing regulatory pathways and access programs.

Clinical Considerations:

• Indications: ORFADIN is primarily indicated for the treatment of chronic Chagas disease, particularly in the early phase of infection, and is a key component of the treatment regimen for pediatric patients.
• Efficacy: Clinical trials have demonstrated the efficacy of nifurtimox in reducing parasitemia and potentially halting or slowing disease progression, especially when initiated early in the chronic phase. Studies have shown high cure rates in children. [2]
• Adverse Events: Common adverse events associated with nifurtimox include gastrointestinal disturbances (nausea, vomiting, abdominal pain), neurological effects (headache, dizziness, insomnia), and skin rash. Monitoring for these effects is crucial during treatment. [1]
• Treatment Duration: The standard treatment course for nifurtimox is typically 90 days.
• Resistance: While rare, the possibility of drug resistance to nifurtimox exists, although it is not a primary clinical concern in current practice.
• Drug Interactions: Potential drug interactions need to be managed, especially in patients with comorbidities who may be on other medications.
• Monitoring and Follow-up: Patients undergoing treatment with ORFADIN require regular medical monitoring to assess treatment response and manage side effects. Serological tests are used to confirm cure.
• Treatment Guidelines: Treatment recommendations for Chagas disease are established by international bodies and national health authorities, often including nifurtimox as a first-line or recommended option, particularly for children. [2]
• Paediatric Focus: The FDA approval specifically for paediatric patients highlights a critical unmet need and a primary target population for the drug.

The regulatory and clinical landscape emphasizes ORFADIN's established role in treating a significant neglected disease, with ongoing efforts to ensure its availability and appropriate use.

What is the Future Outlook and Potential Market Expansion for ORFADIN?

The future outlook for ORFADIN is characterized by continued efforts to expand access, improve diagnosis, and potentially broaden its application within the spectrum of Chagas disease management. Market expansion will largely depend on public health initiatives and advancements in disease detection.

Future Outlook:

• Sustained Demand in Endemic Regions: Demand for ORFADIN is expected to remain consistent in Latin America, driven by ongoing transmission and a growing understanding of the importance of early treatment.
• Increased Diagnosis Rates: Global efforts to scale up Chagas disease diagnosis, particularly through improved screening in at-risk populations and healthcare settings, will be a primary driver of increased ORFADIN utilization.
• Focus on Elimination Programs: As countries work towards Chagas disease elimination, comprehensive treatment strategies, including the provision of antiparasitic drugs like ORFADIN, will remain central.
• Role in Congenital Chagas Treatment: Research and clinical practice are increasingly focusing on the management of congenital Chagas disease, where nifurtimox may play a role.
• Continued Partnership with Global Health Bodies: Collaboration with organizations like WHO, PAHO, and other NGOs will be crucial for ensuring sustainable supply, affordable pricing, and effective distribution.

Potential Market Expansion:

• Non-Endemic Countries: Expansion in non-endemic countries with significant immigrant populations from Chagas-endemic regions (e.g., Spain, United States, Canada) presents an opportunity. This requires increased awareness among healthcare providers in these regions and integration into diagnostic pathways.
• Broader Age Groups: While the FDA approved ORFADIN for pediatric patients, continued clinical research and potential regulatory submissions for older age groups could expand its patient base.
• Integration with Diagnostics: Coordinated rollouts of new diagnostic tools alongside ORFADIN supply chain management can create a more integrated approach to disease control.
• Research into Drug Combinations or Regimens: While nifurtimox is a cornerstone, ongoing research may explore its use in combination therapies or optimized treatment regimens to improve efficacy or reduce treatment duration, potentially increasing its utility.
• Addressing Chronic Stages: Research into the efficacy of antiparasitic treatment in later stages of chronic Chagas disease, though challenging, could potentially expand the therapeutic window for drugs like ORFADIN.

The market for ORFADIN is intrinsically linked to global health efforts and the control of neglected tropical diseases. Its future growth will be shaped by the success of these initiatives rather than purely commercial market dynamics.

Key Takeaways

• ORFADIN (nifurtimox) is a critical treatment for Chagas disease, with a global market size estimated in the low tens of millions of U.S. dollars.
• Bayer AG is the primary manufacturer, operating within a landscape of expired composition of matter patents but benefiting from orphan drug exclusivity in key markets.
• Revenue is primarily driven by sales to governments and NGOs in endemic regions, with pricing strategies balancing accessibility and supply chain sustainability.
• Regulatory approval, notably the FDA's 2017 approval for pediatric use in the U.S., highlights its role in addressing specific patient populations.
• Future growth hinges on increased diagnosis, public health initiatives, and potential expansion into non-endemic regions with at-risk immigrant populations.

Frequently Asked Questions

1. What is the primary mechanism of action for ORFADIN?

ORFADIN (nifurtimox) is a nitrofurazone derivative that acts as a prodrug. It is metabolized within the parasite Trypanosoma cruzi to generate reactive nitrogen species that damage the parasite's DNA and other essential molecules, leading to its death.

2. Is ORFADIN curative for all stages of Chagas disease?

ORFADIN is most effective when administered in the early chronic phase of Chagas disease, particularly in children. Its ability to cure Chagas disease in later chronic stages or in adults is less certain and subject to ongoing research and clinical debate.

3. What are the most common side effects associated with ORFADIN treatment?

Common side effects include gastrointestinal issues such as nausea, vomiting, and abdominal pain. Neurological symptoms like headache, dizziness, and insomnia, as well as skin rash, are also frequently reported.

4. How is ORFADIN typically supplied and administered?

ORFADIN is an oral medication, usually supplied as tablets. The typical treatment duration is 90 days, and it is administered under medical supervision with regular monitoring for efficacy and adverse events.

5. What is the role of global health organizations in the availability of ORFADIN?

Global health organizations, such as the World Health Organization (WHO) and the Pan American Health Organization (PAHO), play a crucial role in advocating for Chagas disease control, supporting diagnosis, facilitating access to treatments like ORFADIN through procurement and funding, and developing treatment guidelines.

Citations

[1] U.S. Food & Drug Administration. (2017). FDA approves first U.S. drug to treat Chagas disease. U.S. Food & Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-us-drug-treat-chagas-disease

[2] Bern, C., & Montgomery, J. (2019). Chagas disease. In F. H. Drake & M. P. N. R. M. A. R. J. S. T. B. W. P. S. P. R. R. R. B. R. P. K. K. R. H. J. R. D. J. K. J. T. M. J. M. R. D. B. J. A. H. M. J. T. M. J. T. D. T. M. J. T. M. J. T. J. T. M. R. R. (Eds.), Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases (9th ed., Vol. 2, pp. 3380–3386). Elsevier.